Efficient sensing of a four-segmented Rift Valley fever virus vaccine candidate by human monocytes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41679332.
- Also identified by DOI 10.1093/infdis/jiag085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The live-attenuated RVFV-4s vaccine against Rift Valley Fever has demonstrated safety and efficacy across multiple animal models and in a phase-I clinical trial. In this study, we examined its impact on innate immune responses and found that RVFV-4s enhances the expression of costimulatory molecules critical for T cell activation, while also triggering proinflammatory responses in primary human monocytes.